{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-100371","form_type":"8-K","ticker":"NEUP","cik":"0001191070","company_name":"Neuphoria Therapeutics Inc.","filed_at":"2025-10-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.946171+00:00","generated_at":"2026-05-17T03:11:28.160200+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Neuphoria Phase 3 trial of BNC210 for social anxiety disorder fails primary endpoint; SAD program discontinued","bullets":["AFFIRM-1 Phase 3 trial did not meet primary endpoint of change in SUDS scores during speech challenge; secondary endpoints also not significant.","Company discontinues further development of SAD program; plans full strategic review of operations and portfolio by year-end.","Cash and equivalents $14.2M as of June 30, 2025; expected to fund operations through Q2 fiscal 2027.","Ongoing Merck partnership: MK-1167 in Phase 2 for Alzheimer's; Neuphoria eligible for up to $450M in milestone payments plus royalties.","Given prior chronic dosing data, Neuphoria will evaluate next steps for BNC210 in PTSD."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-100371","json":"https://secwatch.observer/filing/0001213900-25-100371.json","markdown":"https://secwatch.observer/filing/0001213900-25-100371.md","text":"https://secwatch.observer/filing/0001213900-25-100371.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025100371/0001213900-25-100371-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025100371/ea0261841-8k_neuphoria.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:11:28.160200+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}